75 related articles for article (PubMed ID: 27044808)
21. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
22. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic potentials of microRNA-27a in osteosarcoma.
Tang J; Zhao H; Cai H; Wu H
Biomed Pharmacother; 2015 Apr; 71():222-6. PubMed ID: 25960240
[TBL] [Abstract][Full Text] [Related]
24. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
25. PLA2G16 Expression in Human Osteosarcoma Is Associated with Pulmonary Metastasis and Poor Prognosis.
Liang S; Ren Z; Han X; Yang J; Shan L; Li L; Wang B; Zhang Q; Mu T; Chen K; Xiong S; Wang G
PLoS One; 2015; 10(5):e0127236. PubMed ID: 25993412
[TBL] [Abstract][Full Text] [Related]
26. The association of inhibitor of Growth 4 with its prognostic value in osteogenic sarcoma.
Li F; Sun J; Liu B; Zhang X; Zhou L; Pang J
Int J Clin Exp Pathol; 2017; 10(9):10003-10008. PubMed ID: 31966890
[TBL] [Abstract][Full Text] [Related]
27. Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma.
Wang S; Liu X; He Z; Chen X; Li W
Tumour Biol; 2016 Jan; 37(1):1205-10. PubMed ID: 26282000
[TBL] [Abstract][Full Text] [Related]
28. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma.
Laverdiere C; Hoang BH; Yang R; Sowers R; Qin J; Meyers PA; Huvos AG; Healey JH; Gorlick R
Clin Cancer Res; 2005 Apr; 11(7):2561-7. PubMed ID: 15814634
[TBL] [Abstract][Full Text] [Related]
29. Expression and prognostic relevance of centromere protein A in primary osteosarcoma.
Gu XM; Fu J; Feng XJ; Huang X; Wang SM; Chen XF; Zhu MH; Zhang SH
Pathol Res Pract; 2014 Apr; 210(4):228-33. PubMed ID: 24440098
[TBL] [Abstract][Full Text] [Related]
30. High Expression of HULC Is Associated with Poor Prognosis in Osteosarcoma Patients.
Uzan VR; Lengert Av; Boldrini É; Penna V; Scapulatempo-Neto C; Scrideli CA; Filho AP; Cavalcante CE; de Oliveira CZ; Lopes LF; Vidal DO
PLoS One; 2016; 11(6):e0156774. PubMed ID: 27253450
[TBL] [Abstract][Full Text] [Related]
31. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.
Onda M; Matsuda S; Higaki S; Iijima T; Fukushima J; Yokokura A; Kojima T; Horiuchi H; Kurokawa T; Yamamoto T
Cancer; 1996 Jan; 77(1):71-8. PubMed ID: 8630943
[TBL] [Abstract][Full Text] [Related]
32. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma.
Sun XH; Yang LB; Geng XL; Wang R; Zhang ZC
Int J Clin Exp Pathol; 2015; 8(3):2994-3000. PubMed ID: 26045809
[TBL] [Abstract][Full Text] [Related]
34. Expression of cartilage antitumor component RanBP9 in osteosarcoma.
Zhu LL; Wang CH; Yang HP; Shu WH
J Biol Regul Homeost Agents; 2016; 30(1):103-10. PubMed ID: 27049080
[TBL] [Abstract][Full Text] [Related]
35. Polymeric immunoglobulin receptor expression is correlated with poor prognosis in patients with osteosarcoma.
Wang X; Du J; Gu P; Jin R; Lin X
Mol Med Rep; 2014 Jun; 9(6):2105-10. PubMed ID: 24699841
[TBL] [Abstract][Full Text] [Related]
36. Serum miR-95-3p is a diagnostic and prognostic marker for osteosarcoma.
Niu J; Sun Y; Guo Q; Niu D; Liu B
Springerplus; 2016; 5(1):1947. PubMed ID: 27917340
[TBL] [Abstract][Full Text] [Related]
37. Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.
Baumhoer D; Smida J; Specht K; Bink K; Quintanilla-Martinez L; Rosemann M; Siggelkow H; Nathrath WB; Atkinson MJ; Bielack S; Jundt G; Nathrath M
Hum Pathol; 2011 Jun; 42(6):859-66. PubMed ID: 21292304
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic significance of S100A4 expression in osteosarcoma.
Cao CM; Yang FX; Wang PL; Yang QX; Sun XR
Eur Rev Med Pharmacol Sci; 2014; 18(6):833-9. PubMed ID: 24706307
[TBL] [Abstract][Full Text] [Related]
39. [Correlation of miR-195 with invasiveness and prognosis of breast cancer].
Song CG; Wu XY; Wang C; Fu FM; Shao ZM
Zhonghua Wai Ke Za Zhi; 2012 Apr; 50(4):353-6. PubMed ID: 22800791
[TBL] [Abstract][Full Text] [Related]
40. Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults' age groups and their association with prediction of poor prognosis in human osteosarcoma.
Bahador R; Taheriazam A; Mirghasemi A; Torkaman A; Shakeri M; Yahaghi E; Goudarzi PK
Tumour Biol; 2016 Mar; 37(3):3091-5. PubMed ID: 26423405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
